{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:47:01Z","timestamp":1791586021899,"version":"4.3.4"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2020,8,1]]},"DOI":"10.1001\/jamaoncol.2020.2288","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T17:46:25Z","timestamp":1594921585000},"page":"1256","source":"Crossref","is-referenced-by-count":60,"title":["Association of <i>BRAF<\/i> V600E\/K Mutation Status and Prior BRAF\/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma"],"prefix":"10.1001","volume":"6","author":[{"given":"Igor","family":"Puzanov","sequence":"first","affiliation":[{"name":"Roswell Park Cancer Institute, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Ribas","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[{"name":"Gustave Roussy, Paris-Sud University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Schachter","sequence":"additional","affiliation":[{"name":"The Chaim Sheba Medical Center at Tel Hashomer, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Nyakas","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Daud","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Arance","sequence":"additional","affiliation":[{"name":"Hospital Clinic de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[{"name":"Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, Sydney, New South Wales, Australia"},{"name":"Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"O\u2019Day","sequence":"additional","affiliation":[{"name":"John Wayne Cancer Institute, Providence St John\u2019s Health Center, Santa Monica, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia"},{"name":"Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Margolin","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[{"name":"University Hospital of Z\u00fcrich, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[{"name":"University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Lutzky","sequence":"additional","affiliation":[{"name":"Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Tarhini","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Lin","sequence":"additional","affiliation":[{"name":"Merck & Co, Inc, Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Mogg","sequence":"additional","affiliation":[{"name":"The Bill and Melinda Gates Medical Research Institute, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Homet Moreno","sequence":"additional","affiliation":[{"name":"Merck & Co, Inc, Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nageatte","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Merck & Co, Inc, Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Hamid","sequence":"additional","affiliation":[{"name":"The Angeles Clinic and Research Institute, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"coi200032r2","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.","volume":"29","author":"Long","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi200032r3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/CJI.0000000000000148","article-title":"Sequencing treatment in BRAFV600 mutant melanoma: anti-PD-1 before and after BRAF inhibition.","volume":"40","author":"Johnson","year":"2017","journal-title":"J Immunother"},{"issue":"2","key":"coi200032r6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"issue":"9948","key":"coi200032r7","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"issue":"15","key":"coi200032r8","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma.","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"coi200032r9","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","article-title":"Non-genomic and immune evolution of melanoma acquiring MAPKi resistance.","volume":"162","author":"Hugo","year":"2015","journal-title":"Cell"},{"issue":"12","key":"coi200032r10","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1038\/modpathol.2015.110","article-title":"Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.","volume":"28","author":"Kakavand","year":"2015","journal-title":"Mod Pathol"},{"key":"coi200032r11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/1479-5876-10-107","article-title":"Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.","volume":"10","author":"Ascierto","year":"2012","journal-title":"J Transl Med"},{"issue":"11","key":"coi200032r12","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1002\/cncr.28620","article-title":"Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.","volume":"120","author":"Ackerman","year":"2014","journal-title":"Cancer"},{"issue":"8","key":"coi200032r13","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"coi200032r14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejca.2017.07.022","article-title":"Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.","volume":"86","author":"Hamid","year":"2017","journal-title":"Eur J Cancer"},{"issue":"26","key":"coi200032r15","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"10105","key":"coi200032r16","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"issue":"20","key":"coi200032r17","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"coi200032r18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/annonc\/mdu438.42","article-title":"Pembrolizumab (pembro; MK-3475) for advanced melanoma (MEL): randomized comparison of two dosing schedules.","volume":"25","author":"Robert","year":"2014","journal-title":"Ann Oncol"},{"issue":"6892","key":"coi200032r19","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer.","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"coi200032r20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma.","volume":"10","author":"Ascierto","year":"2012","journal-title":"J Transl Med"},{"issue":"4","key":"coi200032r21","first-page":"756","article-title":"Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.","volume":"63","author":"Satyamoorthy","year":"2003","journal-title":"Cancer Res"},{"issue":"1","key":"coi200032r22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/1758834015616934","article-title":"Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy.","volume":"8","author":"Eroglu","year":"2016","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"coi200032r23","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/jamaoncol.2015.1184","article-title":"Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials.","volume":"1","author":"Larkin","year":"2015","journal-title":"JAMA Oncol"},{"issue":"36","key":"coi200032r24","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification.","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"issue":"34","key":"coi200032r25","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","article-title":"Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma.","volume":"34","author":"Daud","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"coi200032r26","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","article-title":"Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.","volume":"17","author":"Long","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"coi200032r27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma.","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"issue":"5","key":"coi200032r28","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"coi200032r29","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1283462","article-title":"Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma.","volume":"6","author":"Simeone","year":"2017","journal-title":"Oncoimmunology"},{"issue":"7","key":"coi200032r30","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.2017.74.1025","article-title":"Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib.","volume":"36","author":"Long","year":"2018","journal-title":"J Clin Oncol"},{"key":"coi200032r37","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.9531","article-title":"The anti\u2013PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600\u2013mutant melanoma: updated efficacy and safety from parts 1 and 2 of COMBI-i.","author":"Long","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi200032r38","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41591-019-0448-9","article-title":"Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.","volume":"25","author":"Ascierto","year":"2019","journal-title":"Nat Med"},{"key":"coi200032r39","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.9560","article-title":"Safety and preliminary activity data from a single center phase II study of triplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [trident] in patients (Pts) with BRAF-mutated metastatic melanoma (MM).","author":"Tawbi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"coi200032r40","doi-asserted-by":"publisher","first-page":"4992","DOI":"10.1158\/1078-0432.CCR-16-3066","article-title":"Immuno-oncology clinical trial design: limitations, challenges, and opportunities.","volume":"23","author":"Baik","year":"2017","journal-title":"Clin Cancer Res"},{"key":"coi200032r4","author":"KEYTRUDA","year":"2019"},{"key":"coi200032r5","year":"2020"},{"key":"coi200032r1","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines: cutaneous melanoma (version 1, 2020). Accessed January 13, 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx"},{"key":"coi200032r31","unstructured":"Dabrafenib and trametinib followed by ipilimumab and nivolumab or ipilimumab and nivolumab followed by dabrafenib and trametinib in treating patients with stage III-IV BRAFV600 melanoma. ClinicalTrials.gov identifier: NCT02224781. Updated April 3, 2020. Accessed April 3, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02224781"},{"key":"coi200032r32","unstructured":"Sequential combo immuno and target therapy (SECOMBIT) study (SECOMBIT). ClinicalTrials.gov identifier: NCT02631447. Updated June 10, 2019. Accessed April 6, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02631447"},{"key":"coi200032r33","unstructured":"Immunotherapy with ipilimumab and nivolumab preceded or not by a targeted therapy with encorafenib and binimetinib (EBIN). ClinicalTrials.gov identifier: NCT03235245. Updated April 6, 2020. Accessed April 6, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03235245"},{"key":"coi200032r34","unstructured":"Induction therapy with vemurafenib and cobimetinib to optimize nivolumab and ipilimumab therapy (COWBOY). ClinicalTrials.gov identifier: NCT02968303. Updated April 18, 2019. Accessed April 6, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02968303"},{"key":"coi200032r35","unstructured":"Neoadjuvant dabrafenib, trametinib with or without pembrolizumab in BRAF mutant resectable stage III melanoma (NeoTrio).ClinicalTrials.gov identifier: NCT02858921. Updated December 16, 2019. Accessed April 6, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02858921"},{"key":"coi200032r36","unstructured":"Evaluating the efficacy and safety of a sequencing schedule of cobimetinib plus vemurafenib followed by immunotherapy with an anti-PD-L1 antibody in patients with unresectable or metastatic BRAF V600 mutant melanoma (ImmunoCobiVem). ClinicalTrials.gov identifier: NCT02902029. Updated January 31, 2020. Accessed April 6, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02902029"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2768018\/jamaoncology_puzanov_2020_oi_200032_1597168377.80234.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T04:31:14Z","timestamp":1597379474000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2768018"}},"subtitle":["Pooled Analysis of 3 Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2020,8,1]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2020.2288","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,1]]}}}